• Sanofi Pays Kymera $150M to Kick Off Protein Degrader Partnership

    25 days ago - By Xconomy

    Kymera Therapeutics has signed a deal with French biopharma Sanofi to advance two potential treatments for immune-inflammatory diseases that leverage the Cambridge, MA-based company's research into protein degradation, the natural mechanism cells use to get rid of unwanted proteins. Drug developers are eager to leverage that cellular recycling system to create new treatments because it is viewed as a way to potentially get rid of disease-causing proteins that have up until now been considered “undruggable.” Paris-based Sanofi agreed to pay Kymera $150 million upfront for the rights to...
    Read more ...